Gilead Sciences’ SWOT analysis: HIV giant faces challenges, oncology promise

Gilead Sciences Inc. (NASDAQ:GILD), a leading biopharmaceutical company renowned for its HIV therapeutics and expanding oncology franchise, finds itself at a critical juncture. The company’s stock has demonstrated remarkable resilience, delivering a 47.6% return over the past year and outperforming many healthcare sector peers. According to InvestingPro data, Gilead maintains a "GREAT" financial health score of 3.05 out of 5, highlighting its strong market position with a $140.17 billion market capitalization. However, Gilead must navigate a complex landscape of market dynamics, regulatory hurdles, and evolving treatment paradigms to maintain its position and drive future growth.

Financial Performance and Market Position

Gilead’s recent financial performance has been a mixed bag. In early May 2025, the company reported earnings that beat expectations but fell short on revenue estimates. Despite this, Gilead maintained its guidance for both revenue and earnings, suggesting confidence in its near-term outlook. The stock experienced a modest 3% decline following the earnings announcement, indicating that investors were cautiously digesting the news.

As of August 20, 2025, Gilead’s stock price stood at $118.73, reflecting the market’s overall positive sentiment towards the company. With a modest P/E ratio of 22.27 and an attractive dividend yield of 2.8%, Gilead has been one of the stronger performers in the healthcare sector. InvestingPro analysis suggests the stock is currently slightly undervalued, presenting an opportunity for value-oriented investors. Want to discover more undervalued opportunities? Check out our comprehensive list of undervalued stocks.

In terms of valuation, Gilead trades at a discount compared to its large-cap peers. Some analysts suggest that this valuation gap could narrow as the company’s oncology franchise continues to derisk and demonstrate its potential. The company’s market capitalization, as of March 2025, was approximately $137,275 million, underscoring its significant presence in the biotechnology industry.

HIV Franchise: Strengths and Challenges

Gilead’s HIV franchise remains the cornerstone of its business, with a strong portfolio of treatment and prevention options. However, recent developments have introduced new challenges and opportunities in this space.

The company’s newest HIV pre-exposure prophylaxis (PrEP) medication, Yeztugo, has faced setbacks in gaining widespread coverage. In a significant development, CVS Caremark declined to include Yeztugo in its formulary for the upcoming year, citing clinical, financial, and regulatory factors. This decision has raised concerns about the drug’s market acceptance and pricing strategy.

Despite this setback, Gilead’s management remains optimistic about Yeztugo’s prospects. The company has set ambitious goals, aiming to achieve 75% access for Yeztugo within six months and 90% within 12 months. InvestingPro identifies Gilead as a prominent player in the Biotechnology industry, with robust annual revenue of $28.86 billion and strong EBITDA of $13.8 billion, providing substantial resources to support its commercial initiatives. Gilead is banking on the drug’s strong efficacy profile, demonstrated in clinical trials, to eventually secure a mandate from the US Preventative Services Task Force (USPSTF) for coverage.

The potential for government funding cuts presents another challenge for Gilead’s HIV business. Reports of possible reductions in Health and Human Services (HHS) funding for domestic HIV prevention have raised concerns about the impact on Gilead’s PrEP franchise. While the estimated $1.3 billion cut in CDC funding is viewed as a modest headwind rather than a significant threat, it could slow revenue growth for certain products and impact community engagement and testing initiatives.

Oncology Portfolio: A Growing Focus

As Gilead faces challenges in its core HIV business, the company’s oncology franchise is emerging as a key driver of future growth. Analysts have highlighted the positive outlook for this segment, particularly led by products such as Trodelvy and Cell therapies.

The company’s strategic focus on expanding its presence in oncology is seen as a crucial element in diversifying its revenue streams and reducing dependence on the HIV market. As Gilead continues to invest in and develop its oncology pipeline, analysts expect this segment to play an increasingly important role in the company’s overall valuation and growth prospects.

Future Outlook and Strategic Positioning

Looking ahead, Gilead’s future appears to be a balancing act between maintaining its strong position in HIV therapeutics and capitalizing on the growth potential of its oncology portfolio. The company’s pipeline and upcoming product launches are expected to be key factors in driving revenue growth and potentially expanding its market multiples.

One significant milestone on the horizon is the launch of lenacapavir, a long-acting PrEP medication, scheduled for summer 2025. Despite the challenges faced by Yeztugo, analysts anticipate a robust launch for lenacapavir, which could help solidify Gilead’s position in the HIV prevention market.

Gilead’s ability to navigate the evolving healthcare landscape, address pricing pressures, and successfully commercialize its pipeline products will be crucial in determining its long-term success. The company’s strong base business in HIV treatment provides a solid foundation, while its growing oncology franchise offers significant growth potential.

Bear Case

How might CVS’s exclusion of Yeztugo impact Gilead’s market share in HIV prevention?

CVS Caremark’s decision to exclude Yeztugo from its formulary raises concerns about Gilead’s ability to gain widespread acceptance for its new HIV prevention drug. This exclusion could significantly limit patient access to Yeztugo, potentially impacting Gilead’s market share in the competitive PrEP landscape. If other major pharmacy benefit managers follow CVS’s lead, it could create a domino effect, further challenging Gilead’s ambitious access goals for Yeztugo.

The exclusion also highlights potential pricing issues for Yeztugo, especially when compared to existing oral therapies. If Gilead struggles to demonstrate the cost-effectiveness of Yeztugo relative to daily pills, it may face ongoing challenges in securing favorable formulary positions. This could result in slower-than-expected uptake of the drug and potentially impact Gilead’s revenue projections for its HIV prevention portfolio.

What risks does Gilead face from potential government funding cuts to HIV prevention programs?

The reported potential cuts to HHS funding for domestic HIV prevention programs pose a significant risk to Gilead’s PrEP franchise. A reduction in government funding could lead to decreased community engagement, fewer testing initiatives, and reduced access to HIV prevention services. This, in turn, could slow the growth of the overall PrEP market, impacting Gilead’s revenue from both existing and new HIV prevention products.

Moreover, if funding cuts result in fewer people being tested for HIV or accessing prevention services, it could undermine public health efforts to combat HIV transmission. This broader impact on HIV prevention efforts could create a challenging environment for Gilead to launch and promote new PrEP medications, potentially affecting the company’s long-term strategy in this therapeutic area.

Bull Case

How could Gilead’s oncology portfolio drive future growth and valuation expansion?

Gilead’s growing oncology portfolio presents a significant opportunity for future growth and potential valuation expansion. The company’s focus on developing innovative cancer therapies, particularly with products like Trodelvy and its Cell therapy pipeline, positions it well in the rapidly evolving oncology market. As these products gain traction and demonstrate efficacy across various cancer types, they could become major revenue drivers for Gilead.

The oncology market is known for its high-value treatments and substantial growth potential. As Gilead continues to invest in and expand its oncology franchise, it could diversify its revenue streams and reduce its dependence on the HIV market. Success in oncology could lead to multiple expansion for Gilead’s stock, as investors recognize the company’s potential beyond its traditional focus areas. This diversification could also provide a buffer against challenges in other segments of Gilead’s business.

What advantages does Gilead have in the HIV treatment and prevention market?

Despite recent challenges, Gilead maintains several key advantages in the HIV treatment and prevention market. The company’s long-standing leadership in this therapeutic area has resulted in a strong portfolio of established products and a deep pipeline of innovative treatments. Gilead’s expertise in HIV therapeutics gives it a significant edge in developing new, long-acting treatments like lenacapavir, which could revolutionize HIV prevention.

Gilead’s strong relationships with healthcare providers, advocacy groups, and regulatory bodies in the HIV space provide a solid foundation for launching new products and navigating market challenges. The company’s established distribution networks and marketing infrastructure specifically tailored to HIV therapeutics allow for efficient commercialization of new treatments.

Furthermore, Gilead’s financial strength and commitment to HIV research position it well to weather short-term setbacks and continue investing in long-term solutions. As the global focus on ending the HIV epidemic intensifies, Gilead’s comprehensive approach to HIV treatment and prevention could lead to new opportunities and partnerships, reinforcing its market leadership.

SWOT Analysis

Strengths:

• Strong leadership position in HIV therapeutics
• Growing and promising oncology portfolio
• Robust pipeline of innovative treatments
• Strong financial position and cash flow

Weaknesses:

• Challenges in securing coverage for new HIV prevention drug Yeztugo
• Revenue miss in recent earnings report
• Dependence on HIV franchise for significant portion of revenue

Opportunities:

• Expansion of oncology franchise
• Launch of long-acting PrEP medication lenacapavir
• Potential for multiple expansion as oncology portfolio derisks
• Growing global focus on HIV prevention and treatment

Threats:

• Potential government funding cuts to HIV prevention programs
• Increasing competition in both HIV and oncology markets
• Pricing pressures and scrutiny from payers and regulators
• Risks associated with clinical trial outcomes and regulatory approvals

Analysts Targets

• BMO Capital Markets: $130 (August 21, 2025)
• BMO Capital Markets: $115 (March 19, 2025)

This analysis is based on information available up to August 21, 2025.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on GILD. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore GILD’s full potential at InvestingPro.

Should you invest in GILD right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if GILD is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate GILD further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if GILD appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.